Human Microbiome Market Is Extrapolated to Reach a Value of $1.7 Billion at a Growing CAGR of 36.1% by 2029
In November 2021, Seres Therapeutics collaborated with Bacthera to manufacture SER-109. The company is a leading manufacturer for recurrent Clostridioides difficile infection (rCDI). As per the agreement, Bacthera is establishing a dedicated facility for commercial manufacturing in its new Microbiome Center of Excellence, a manufacturing site dedicated to the production of LBPs located on Lonza's Ibex campus in Visp, Switzerland.
View full press release